3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 1/2
1
Phase 1
1
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
13
Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Lung Neoplasms
9
Prostatic Neoplasms
7
Recurrence
6
Neoplasm Metastasis
6
Head and Neck Neoplasms
6
Carcinoma, Hepatocellular
6
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Squamous Cell
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Melanoma
4
Liver Neoplasms
4
Endometrial Neoplasms
4
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Hematologic Neoplasms
3
Fatigue
3
Esophageal Neoplasms
3
Depression
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Rectal Neoplasms
2
Interventions
valrubicin
1
Oncolytic Virotherapy
1
Mitomycin
1
Interferons
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Terminated
×
Adenoviridae Infections
×
Clear all
NCT05305040
2024-05-16
Prevent
AlloVir
Phase 2/3
Terminated
451 enrolled
10 charts
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled